Citadel Advisors’s NextCure NXTC Stock Holding History

Citadel Advisors’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,150	Closed	-$71K	–	15273
2022 Q3	$71K	Sell	2,150 -183	-8%	-$9.33K	﹤0.01%	11372
2022 Q2	$132K	Buy	+2,333	New	+$122K	﹤0.01%	11113
2021 Q2	–	Sell	-10,942	Closed	-$1.31M	–	14179
2021 Q1	$1.31M	Buy	10,942 +6,059	+124%	+$877K	﹤0.01%	7434
2020 Q4	$639K	Buy	+4,883	New	+$631K	﹤0.01%	7680
2020 Q2	–	Sell	-533	Closed	-$237K	–	10286
2020 Q1	$237K	Sell	533 -75	-12%	-$40.1K	﹤0.01%	7723
2019 Q4	$411K	Buy	+608	New	+$305K	﹤0.01%	7116

Other funds holding NXTC

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Verdad Advisers Boston, Massachusetts $104M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Citadel Advisors's NXTC Position: Q2 2026 in Review

Citadel Advisors sold out of NextCure (NXTC) in Q2 2026, closing a stake of 15,292 shares — an estimated $161K sold.

Citadel Advisors first reported a position in NXTC in Q2 2019 and held it in 26 quarters. The position peaked at $44.9M in Q4 2019. 30 funds tracked by Wall St. Rank hold NXTC as of Q2 2026.

Citadel Advisors reported no remaining NextCure position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 15,292 NextCure shares in Q2 2026, an estimated $161K.
Citadel Advisors first reported a position in NextCure in Q2 2019 and held it in 26 quarters.
Citadel Advisors's NextCure position peaked at $44.9M in Q4 2019.
30 funds tracked by Wall St. Rank held NextCure as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.